236 results
Page 2 of 12
8-K
kzg17wc1
6 Dec 22
Regulation FD Disclosure
4:02pm
8-K
EX-99.1
wdyth0j hb
6 Dec 22
Regulation FD Disclosure
4:02pm
425
3lbdzeyh0zbfxi p69va
5 Dec 22
Business combination disclosure
9:28am
8-K
EX-99.1
hu3vm9mb63 iojc8xj
5 Dec 22
Yumanity Therapeutics Declares Special Dividend In Connection with Proposed Asset Sale to Janssen and Merger with Kineta
9:27am
8-K
4plv6
5 Dec 22
Yumanity Therapeutics Declares Special Dividend In Connection with Proposed Asset Sale to Janssen and Merger with Kineta
9:27am
424B3
az593x2zzqj2d3vr
5 Dec 22
Prospectus supplement
9:22am
425
3sarmqzdpu3j2coveyx2
1 Dec 22
Business combination disclosure
4:04pm
8-K
EX-99.1
3ordsunzag 40f
1 Dec 22
Kineta to Present KVA12123 VISTA Blocking Immunotherapy Program at Antibody Engineering and Therapeutics Conference
4:01pm
8-K
304zi9412xxs8j9tmk
1 Dec 22
Kineta to Present KVA12123 VISTA Blocking Immunotherapy Program at Antibody Engineering and Therapeutics Conference
4:01pm
425
md331hjg7
29 Nov 22
Business combination disclosure
4:03pm
8-K
38zdtxeb1d4wccj7oas
29 Nov 22
Kineta to Participate in JMP Securities Hematology and Oncology Summit
4:01pm
8-K
EX-99.1
ddbi5u
29 Nov 22
Kineta to Participate in JMP Securities Hematology and Oncology Summit
4:01pm
425
k2dkuc9gasue66gftp9
28 Nov 22
Business combination disclosure
4:03pm
8-K
1qx7xbp9bqw6mm
28 Nov 22
Regulation FD Disclosure
4:01pm
425
t7q4mh8x33
15 Nov 22
Business combination disclosure
4:03pm
8-K
8xh5go2tc
15 Nov 22
Kineta Announces FDA Acceptance of Investigational New Drug (IND) Application for KVA12123 for the Treatment of Advanced Solid Tumors
4:02pm
8-K
EX-99.1
2sg0 kzpw
15 Nov 22
Kineta Announces FDA Acceptance of Investigational New Drug (IND) Application for KVA12123 for the Treatment of Advanced Solid Tumors
4:02pm
425
9gh1dxnwx35pwumg
14 Nov 22
Business combination disclosure
8:50am
8-K
x3xjk 62hyp0t
14 Nov 22
Yumanity Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Developments
8:37am